drugset / Trial / NCT01752842

Summary

This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease.

Timeline

Start
2013-03
Primary completion
2018-02-23
Completion
2018-02-23

Outcome

Missed primary endpoint

registry analysis (superiority test); Fenofibrate vs Placebo for Fenofibrate; p = 0.07; Mean Difference (Final Values) -0.75 (95% CI -1.56 to 0.04); ANCOVA NCT01752842 ↗

registry analysis (superiority test); Fenofibrate vs Placebo for Fenofibrate; p = 0.8128; Mean Difference (Final Values) 0.0058 (95% CI -0.0418 to 0.0543); ANCOVA NCT01752842 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 160 mg —